Sign in
WithdrawnNo phase

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Key facts

Who runs it
Dartmouth-Hitchcock Medical Center
Where
Lebanon, United StatesSee the site
Trial code
Status
Withdrawn
Started
31 Mar 2022
Ended
Dec 2023
Type of study
Interventional
Treatments tested
  • Fibroscan
Record updated
13 July 2023
Why it stopped
No participants enrolled

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Men and women ≥ 18 with CF and one of the following:; Normal OGTT; Elevated OGTT; Known CFRD

Who cannot take part

  • Men and women without CF

Where in United States

  • Dartmouth Hitchcock Medical CenterLebanon, United States

About the trial

What the trial wants to find out

This study proposes to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis.

The group in the trial

  • FibroscanOther group

    One study visit for fibroscan measurement of the liver.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 July 2023